Skip to main content
logo
RIT Capital Partners Plc (LON:RCP)
London flag London · Delayed Price · Currency is GBP · Price in GBX
1,956.00
+8.00 (0.41%)
Aug 13, 2025, 11:44 AM BST

Inozyme Pharma Revenue

RIT Capital Partners had revenue of 145.00M GBP in the half year ending June 30, 2025, with 28,900.00% growth. This brings the company's revenue in the last twelve months to 347.30M, up 10.29% year-over-year. In the year 2024, RIT Capital Partners had annual revenue of 375.30M with 163.55% growth.

Revenue (ttm)
347.30M
Revenue Growth
+10.29%
P/S Ratio
7.79
Revenue / Employee
5.69M
Employees
61
Market Cap
2.71B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024375.30M232.90M163.55%
Dec 31, 2023142.40M671.20M-126.93%
Dec 31, 2022-528.80M-1.45B-157.58%
Dec 31, 2021918.30M377.10M69.68%
Dec 31, 2020541.20M133.70M32.81%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
HSBC Holdings41.03B
London Stock Exchange Group9.14B
Barclays25.65B
Lloyds Banking Group17.67B
NatWest Group14.86B
3i Group5.15B
Standard Chartered14.69B
Prudential9.79B
Revenue Rankings

RIT Capital Partners News

More News